TTM2试验结局报告与随访方案:院外心脏骤停后目标低温与目标正常体温比较
TTM2试验是一项多中心随机临床试验,比较院外心脏骤停后33°C目标温度管理与正常体温及早期发热治疗(≥37.8°C)。本文介绍TTM2试验随访的设计与原理,随访将收集次要和探索性结局信息。盲法结局评估者于心脏骤停后30天进行电话访谈,包括改良Rankin量表(mRS)和格拉斯哥结局扩展量表(GOSE);6和24个月进行面对面评估,包括临床医生报告的mRS、GOSE,患者报告的EQ-5D-5L、生活满意度、两个简单问题,观察者报告的IQCODE-CA及神经认知表现测试MoCA、SDMT。探索性分析重点关注幸存者脑损伤,比较两组神经认知功能(MoCA、SDMT)和社会参与(GOSE)的潜在差异。
要点
- TTM2试验为多中心随机临床试验,比较院外心脏骤停后33°C目标温度管理与正常体温及早期发热治疗(≥37.8°C)。
- 盲法结局评估者于心脏骤停后30天电话访谈评估mRS和GOSE。
- 6和24个月面对面评估包括临床医生报告mRS、GOSE,患者报告EQ-5D-5L、生活满意度、两个简单问题,观察者报告IQCODE-CA及MoCA、SDMT。
- 探索性分析比较两组幸存者神经认知功能(MoCA、SDMT)和社会参与(GOSE)的潜在差异。
- 随访方案为务实但详细的预先计划标准化评估,旨在确保数据质量、减少缺失数据。
适用人群与场景
- 院外心脏骤停(OHCA)患者,纳入TTM2试验者。
处置流程与药物剂量
- 盲法结局评估者于心脏骤停后30天进行电话访谈,评估改良Rankin量表(mRS)和格拉斯哥结局扩展量表(GOSE)。
- 于6和24个月进行面对面评估,包括临床医生报告的mRS、GOSE;患者报告的EQ-5D-5L、生活满意度、两个简单问题;观察者报告的IQCODE-CA及神经认知表现测试MoCA、SDMT。
研究设计与关键结果
- TTM2试验为多中心随机临床试验,比较院外心脏骤停后33°C目标温度管理与正常体温及早期发热治疗(≥37.8°C)。
- 随访于30天电话访谈评估mRS和GOSE,6和24个月面对面评估mRS、GOSE、EQ-5D-5L、生活满意度、两个简单问题、IQCODE-CA、MoCA、SDMT。
- 探索性分析比较两组幸存者神经认知功能(MoCA、SDMT)和社会参与(GOSE)的潜在差异。
证据类型、等级与局限
- 证据类型:多中心随机临床试验的随访方案设计文章。
- 局限:原文未报告局限性。
对床旁实践的改变
- 该随访方案采用盲法结局评估者、多来源信息(临床医生报告、患者报告、观察者报告)及神经认知表现测试,旨在确保数据质量、减少缺失数据。
- 探索性分析重点关注幸存者脑损伤,比较两组神经认知功能(MoCA、SDMT)和社会参与(GOSE)的潜在差异。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
AIMS: The TTM2-trial is a multi-centre randomised clinical trial where targeted temperature management (TTM) at 33 °C will be compared with normothermia and early treatment of fever (≥37.8 °C) after Out-of-Hospital Cardiac Arrest (OHCA). This paper presents the design and rationale of the TTM2-trial follow-up, where information on secondary and exploratory outcomes will be collected. We also present the explorative outcome analyses which will focus on neurocognitive function and societal participation in OHCA-survivors.
METHODS: Blinded outcome-assessors will perform follow-up at 30-days after the OHCA with a telephone interview, including the modified Rankin Scale (mRS) and the Glasgow Outcome Scale Extended (GOSE). Face-to-face meetings will be performed at 6 and 24-months, and include reports on outcome from several sources of information: clinician-reported: mRS, GOSE; patient-reported: EuroQol-5 Dimensions-5 Level responses version (EQ-5D-5L), Life satisfaction, Two Simple Questions; observer-reported: Informant Questionnaire on Cognitive Decline in the Elderly-Cardiac Arrest version (IQCODE-CA) and neurocognitive performance measures: Montreal Cognitive Assessment, (MoCA), Symbol Digit Modalities Test (SDMT). Exploratory analyses will be performed with an emphasis on brain injury in the survivors, where the two intervention groups will be compared for potential differences in neuro-cognitive function (MoCA, SDMT) and societal participation (GOSE). Strategies to increase inter-rater reliability and decrease missing data are described.
DISCUSSION: The TTM2-trial follow-up is a pragmatic yet detailed pre-planned and standardised assessment of patient's outcome designed to ensure data-quality, decrease missing data and provide optimal conditions to investigate clinically relevant effects of TTM, including OHCA-survivors' neurocognitive function and societal participation.
参考来源
- Lilja G, Nielsen N, Ullén S, et al. Protocol for outcome reporting and follow-up in the Targeted Hypothermia versus Targeted Normothermia after Out-of-Hospital Cardiac Arrest trial (TTM2). Resuscitation. 2020. PMID: 32205155. doi:10.1016/j.resuscitation.2020.03.004
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。